The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

In the treatment of women with abnormal uterine bleeding, once a thorough history, physical
examination, and indicated imaging studies are performed and all significant structural …

Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss (MBL)> 80
mL per cycle, that interferes with a woman's physical, emotional, social wellbeing and quality …

Preliminary data and clinical experience have suggested an increased risk of abnormal
uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid …

Introduction Rivaroxaban is a convenient oral anticoagulant for patients with venous
thromboembolism (VTE). The impact of rivaroxaban and vitamin K antagonists (VKAs) on …

Contraceptive counselling should begin early in females with heart disease, preferably
directly after the start of menstruation. In coming to a decision about the method of …

Although highly effective, warfarin use is complicated by its unpredictable narrow
therapeutic window, genetic heterogeneity in pharmacokinetic response, numerous food …

The article discusses the association of heavy menstrual bleeding (HMB) with direct oral
anticoagulant (DOAC) rivaroxaban therapy. Topics mentioned include the use for treating …

Menstrual suppression to provide relief of menstrual-related symptoms or to manage
medical conditions associated with menstrual morbidity or menstrual exacerbation has been …

The direct oral anticoagulants (DOACs) are therapeutic alternatives to warfarin and other
vitamin K antagonists (VKAs), and constitute the standard of care for many indications. VKAs …